Seeking Alpha

Coherus Granted Permanent, Product-Specific Q-Code for CIMERLI® (ranibizumab-eqrn) from the Centers for Medicare and Medicaid Services

Coherus Solutions ™ offers healthcare professionals comprehensive practice and patient support that includes extensive patient assistance, industry-leading electronic services, and office support to ...
Business Wire

FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susvimo ...
The American Journal of Managed Care

FDA Approves Ranibizumab Implant in Treatment of DME

Ranibizumab implants approved by FDA for DME offer a more convenient treatment schedule, reducing injection frequency significantly. The phase 3 Pagoda study showed noninferior visual acuity with ...
Verywell Health on MSN

New diabetic macular edema treatment cuts monthly eye injections to twice a year

Fact checked by Jennifer Klump Key Takeaways Susvimo is an FDA-approved eye implant for diabetic macular edema that can be refilled every six months instead of requiring monthly injections.Diabetic ...
Seeking Alpha

CIMERLI® (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch

REDWOOD CITY, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (CHRS), today announced that sales of CIMERLI® (ranibizumab-eqrn) to retinal specialists have exceeded 100,000 doses ...
Healio

No unexpected adverse events for ranibizumab biosimilars in initial clinical experience

Please provide your email address to receive an email when new articles are posted on . SEATTLE — Initial experience with two ranibizumab biosimilars showed no unexpected adverse events, according to ...
Medscape

FDA Approves Ranibizumab for Diabetic Macular Edema

August 10, 2012 — The US Food and Drug Administration (FDA) has approved ranibizumab (Lucentis, Genentech) intravitreal injection for the treatment of diabetic macular edema (DME), according to an ...
The American Journal of Managed Care

Visual Acuity, Retinal Sensitivity Improved With Intravitreal Ranibizumab Injection

An intravitreal ranibizumab injection was able to improve retinal sensitivity and thickness along with improving visual acuity. Branch retinal vein occlusion (BRVO) can affect people aged 40 years and ...
Business Wire

Genentech’s Susvimo Maintains Vision Over Five Years With Two Refills Per Year in People With Wet Age-Related Macular Degeneration (AMD)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new, five-year efficacy, safety and durability data from the Phase ...
Medscape

'Encouraging' Real-life Data on Ranibizumab in Wet AMD

NICE, France — Visual acuity remains stable or continues to improve over 5 years in most patients treated with ranibizumab (Lucentis, Genentech) for neovascular age-related macular degeneration under ...
Nasdaq

Coherus Granted Permanent, Product-Specific Q-Code for CIMERLI® (ranibizumab-eqrn) from the Centers for Medicare and Medicaid Services

REDWOOD CITY, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that the Centers for Medicare and Medicaid Services (CMS) has published a ...